Clinical Trial

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 2, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-07.
Trial Details
NCT Number NCT07272343
Lead Sponsor Second Affiliated Hospital of Nanchang University
Conditions Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
Enrollment 100 participants
Start Date 2023-02-10
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-02